Amarillo Biosciences, Inc. (AMAR) is a specialty biopharmaceutical company dedicated to the development of oral administration of interferon alpha (IFNa), as a human and animal therapeutic. In the United States, the Company stock is publicly traded OTCBB:AMAR. In Germany, the Company stock is publicly traded on the Frankfurt, Stuttgart, Berlin-Bremen and Xetra exchanges as FZX WKN 917640.
Website: www.amarbio.com